Innate Pharma S.A.'s filings document the company's foreign private issuer reporting, oncology pipeline disclosures, governance matters, and share-capital information. Form 6-K reports furnish company press releases covering clinical-stage immunotherapy programs, business updates, investor and scientific conference activity, Annual General Meeting materials, and French share and voting-right notifications.
The company's Form 20-F annual report and Universal Registration Document address annual financial reporting, management discussion, corporate governance, statutory auditor reports, and risk factors for a biotechnology issuer developing antibody therapeutics. Filings also reference registration statements on Form F-3 and Form S-8 and disclose Nasdaq and Euronext Paris trading identifiers.
Innate Pharma SA reported its third-quarter 2026 business and financial update. Cash, cash equivalents and financial assets were €96.8 million as of September 30, 2026, and financial liabilities were €16.2 million on that date. The company anticipates a cash horizon until the end of Q1 2028. Revenue for the first nine months of 2026 was €3.4 million, compared with €2.3 million in the same period of 2025. The cash figure includes the $75 million Sobi upfront payment and aggregate gross proceeds from the €30 million ordinary-share private placement in August 2026.
IPH4502 Phase 1 dose-escalation enrollment is complete, with 76 patients enrolled; data are scheduled for presentation November 18, 2026. First patient dosing in lacutamab’s Phase 3 TELLOMAK-3 is expected in Q1 2027; an FDA accelerated approval filing in Sézary syndrome is planned for H2 2027 once TELLOMAK-3 is underway. The AstraZeneca-led PACIFIC-9 readout is expected in the first half of 2027, revised from the second half of 2026 because the study is event-driven. Chief Financial Officer Frédéric Lombard will step down December 31, 2026, and Innate has initiated a search for a replacement.
Innate Pharma SA (IPHA) said AstraZeneca updated the expected high-level data readout for PACIFIC-9 to the first half of 2027, from the second half of 2026. The revised timing reflects the study’s event-driven nature. PACIFIC-9 is an AstraZeneca-led Phase 3 trial evaluating durvalumab with monalizumab or oleclumab in patients with unresectable Stage III non-small cell lung cancer who have not progressed following platinum-based chemoradiation therapy; enrollment is complete. Innate developed monalizumab in collaboration with AstraZeneca.
Innate Pharma SA announced that members of its executive team will participate in the Stifel Healthcare Conference in New York, November 10–12, 2026, and the Jefferies Global Healthcare Conference in London, November 16–19, 2026. A Stifel fireside chat is scheduled for November 10, 2026, at 2:00 p.m. ET / 8:00 p.m. CET; its live webcast link will be available on the company’s investor Events page, and a replay will be available following the event. Innate describes its proprietary pipeline as centered on antibody-drug conjugates, led by IPH4502, and identifies lacutamab with Sobi and monalizumab with AstraZeneca as partnered assets.
Innate Pharma SA will hold a conference call on November 5, 2026, at 2:00 p.m. CET / 8:00 a.m. ET for a business and financial update for the third quarter of 2026. Participants include Chief Executive Officer Jonathan Dickinson, Chief Medical Officer Markus Jensen, Chief Operating Officer Yannis Morel, Stéphanie Cornen, Vice President of Investor Relations and Communications, and Frédéric Lombard, Senior Vice President and Chief Financial Officer. A webcast replay will be available on the company’s website for 90 days following the event.
Innate Pharma SA (IPHA) reported first-half 2026 results marked by a major partnering deal and restructuring. The company entered a strategic partnership with Sobi for lacutamab, triggering a USD 75 million upfront payment on September 16, 2026 and enabling initiation of the TELLOMAK-3 Phase 3 CTCL trial, with first patient targeted in Q1 2027 and potential accelerated approval in Sézary syndrome. Innate is also eligible for up to USD 505 million in additional milestones and tiered double-digit royalties.
During and shortly after the period, Innate completed a €30 million equity financing (17,647,059 new shares at €1.70) and estimates its cash horizon extends to the end of Q1 2028, factoring in the Sobi upfront and this capital increase. As of June 30, 2026, cash, cash equivalents, short-term investments and financial assets were €21.4 million, with net cash of about €0.1 million and financial debt of €20.2 million, while collaboration liabilities related to monalizumab totaled €39.6 million.
Revenue and other income rose to €5.7 million, but Innate recorded a net loss of €19.6 million, albeit improved from €21.3 million a year earlier, helped by reduced operating expenses. R&D spending fell to €16.9 million and G&A to €7.8 million, reflecting workforce reductions and portfolio focus around IPH4502 and late-stage partnered assets.
Innate Pharma SA (IPHA) reported first-half 2026 revenue and other income of €5.7 million, up from €4.9 million a year earlier, and a net loss of €19.6 million versus €21.3 million. Operating expenses fell to €24.7 million (from €30.3 million) as R&D and G&A were reduced following restructuring.
Cash, cash equivalents and financial assets declined to €21.4 million at June 30, 2026 (from €44.8 million at December 31, 2025), with net cash of €0.1 million and collaboration debt of €39.6 million plus €20.1 million of bank borrowings. Operating activities used €21.0 million of cash in the half. Shareholders’ equity was negative at €40.5 million.
The company highlights significant post-period financing: a USD 75 million upfront licensing and commercialization agreement with Sobi for lacutamab and an August 2026 private placement raising about €30 million. After these transactions, management estimates having sufficient liquidity to fund planned operations until the first quarter of 2028, and the financial statements are prepared on a going-concern basis.
Innate Pharma S.A. (IPHA) reports that its previously announced strategic partnership with Sobi for the T‑cell lymphoma drug candidate lacutamab is now effective, following expiration of applicable antitrust waiting periods and completion of other closing conditions. Transaction closing triggers a USD 75 million upfront payment to Innate and the initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T‑cell lymphoma, with first patient expected in Q1 2027. Under the agreement, Innate will conduct TELLOMAK-3 to support applications for full approvals in Sézary syndrome and mycosis fungoides, while Sobi receives exclusive global commercialization rights to lacutamab upon potential accelerated approval and may assume full global development rights after positive Phase 3 results.
Innate Pharma S.A. (IPHA) announced it will host a conference call and webcast on September 17, 2026 to provide a business update for the first half of 2026. The event will feature the company’s senior leadership, including the Chief Executive Officer, Chief Medical Officer, Chief Operating Officer, and Chief Financial Officer.
Innate Pharma is a clinical-stage biotechnology company focused on immunotherapies for cancer, with a proprietary pipeline centered on antibody-drug conjugates such as IPH4502 targeting Nectin-4, and partnered late-stage assets lacutamab with Sobi and monalizumab with AstraZeneca. The webcast replay will be available for 90 days on the company’s website.
Innate Pharma S.A. (IPHA), a clinical-stage biotechnology company focused on immunotherapies for cancer, reported that members of its executive team will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York, United States, on September 14–16, 2026. A fireside chat is scheduled for September 14, 2026 at 4:30 PM EDT / 10:30 PM CEST, with a live webcast and replay accessible via the Investors section of Innate Pharma’s website. The company highlights a pipeline centered on antibody-drug conjugates, led by IPH4502 targeting Nectin-4 for solid tumors, alongside partnered late-stage assets lacutamab with Sobi for cutaneous T-cell lymphomas and monalizumab with AstraZeneca for non-small cell lung cancer.
Innate Pharma S.A. (IPHA) completed a primary private placement of 17,647,059 new ordinary shares at €1.70 per share, raising approximately €30.0 million in gross proceeds through a capital increase without preferential subscription rights under previously approved shareholder resolutions.
After paying placement fees and estimated expenses of about €2.4 million, Innate expects net proceeds of roughly €27.6 million. The shares were placed with qualified institutional buyers in the United States under Section 4(a)(2) of the Securities Act and with qualified and institutional investors outside the United States under Regulation S. The new shares are approved for listing on Euronext Paris on the same line as existing ordinary shares; no new ADSs were issued and the new shares cannot be deposited into the ADS program.
Innate plans to use the net proceeds primarily to continue clinical development of its Nectin-4 ADC IPH4502, advance its preclinical ADC portfolio, and for working capital and general corporate purposes. The company and most directors and certain executives agreed to 90‑day lock‑up restrictions following closing. Separately, management disclosed that existing cash and investments provide runway to the end of Q3 2026, and that, before this offering and assuming a USD 75 million upfront payment from its strategic partnership with Sobi, runway was anticipated to extend through Q3 2027.